ANVS
NYSE
$1.70
Annovis Bio Inc (ANVS)
Annovis Bio, Inc., a clinical-stage drug platform company, develops drugs to treat neurodegeneration. The company is headquartered in Berwyn, Pennsylvania.
Sector:
Healthcare
Industry:
Biotechnology
Strong Buy
Target: $11 (+547.06%)
Market Cap
$52M
FCF 5Y CAGR
+37.11%
Free Cash Flow Yield
-51.37%
Beta (5Y)
1.59
Price Chart
Valuation
Market Cap$52M
P/B23.95
Profitability
EBITDA-$41M
EPS-$1.66
Financial Health
Free Cash Flow Yield-51.37%
Growth & Risk
EPS 5Y CAGR+6.84%
FCF 5Y CAGR+37.11%
Beta (5Y)1.59
Sharpe Ratio-0.13